参考文献/References:
[1] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.DOI:10.1038/nrc3239.
[2] Postow MA,Sidlow R,Hellmann MD.Immune-related adverse events associated with immune checkpoint blockade[J].N Engl J Med,2018,378(2):158-168.DOI:10.1056/NEJMra1703481.
[3] Darnell EP,Mooradian MJ,Baruch EN,et al.Immune-related adverse events(irAEs):diagnosis,management,and clinical pearls [J].Curr Oncol Rep,2020,22(4):39.DOI:10.1007/s11912-020-0897-9.
[4] Godwin JL,Jaggi S,Sirisena I,et al.Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer [J].J Immunother Cancer,2017,5:40.DOI:10.1186/s40425-017-0245-2.
[5] Baden MY,Imagawa A,Abiru N,et al.Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy [J].Diabetol Int,2018,10(1):58-66.DOI:10.1007/s13340-018-0362-2.
[6] Kotwal A,Haddox C,Block M,et al.Immune checkpoint inhibitors:an emerging cause of insulin-dependent diabetes[J].BMJ Open Diabetes Res Care,2019,7(1):e000591.DOI:10.1136/bmjdrc-2018-000591.
[7] Stamatouli AM,Quandt Z,Perdigoto AL,et al.Collateral damage:insulin-dependent diabetes induced with checkpoint inhibitors[J].Diabetes,2018,67(8):1471-1480.DOI:10.2337/dbi18-0002.
[8] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.DOI:10.3322/caac.21551.
[9] Guleria I,Gubbels Bupp M,Dada S,et al.Mechanisms of PDL1-mediated regulation of autoimmune diabetes[J].Clin Immunol,2007,125(1):16-25.DOI:10.1016/j.clim.2007.05.013.
[10] Ben Nasr M,Tezza S,D'Addio F,et al.PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes [J].Sci Transl Med,2017,9(416):eaam7543.DOI:10.1126/scitranslmed.aam7543.
[11] Fujisawa R,Haseda F,Tsutsumi C,et al.Low programmed cell death-1(PD-1)expression in peripheral CD4(+)T cells in Japanese patients with autoimmune type 1 diabetes [J].Clin Exp Immunol,2015,180(3):452-457.DOI:10.1111/cei.12603.
[12] Colli ML,Hill JLE,Marroquí L,et al.PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction [J].EBioMedicine,2018,36:367-375.DOI:10.1016/j.ebiom.2018.09.040.
[13] Osum KC,Burrack AL,Martinov T,et al.Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes [J].Sci Rep,2018,8(1):8295.DOI:10.1038/s41598-018-26471-9.
[14] Wei SC,Duffy CR,Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer Discov,2018,8(9):1069-1086.DOI:10.1158/2159-8290.CD-18-0367.
[15] Iwama S,De Remigis A,Callahan MK,et al.Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J].Sci Transl Med,2014,6(230):230ra245.DOI:10.1126/scitranslmed.3008002.
[16] Buchbinder EI,Desai A.CTLA-4 and PD-1 pathways:similarities,differences,and implications of their inhibition[J].Am J Clin Oncol,2016,39(1):98-106.DOI:10.1097/COC.0000000000000239.
[17] de Filette JMK,Pen JJ,Decoster L,et al.Immune checkpoint inhibitors and type 1 diabetes mellitus:a case report and systematic review[J].Eur J Endocrinol,2019,181(3):363-374.DOI:10.1530/EJE-19-0291.
[18] Wright JJ,Salem JE,Johnson DB,et al.Increased reporting of immune checkpoint inhibitor-associated diabetes[J].Diabetes Care,2018,41(12):e150-e151.DOI:10.2337/dc18-1465.
[19] Tsang VHM,McGrath RT,Clifton-Bligh RJ,et al.Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes[J].J Clin Endocrinol Metab,2019,104(11):5499-5506.DOI:10.1210/jc.2019-00423.
[20] Akturk HK,Kahramangil D,Sarwal A,et al.Immune checkpoint inhibitor-induced type 1 diabetes:a systematic review and meta-analysis[J].Diabet Med,2019,36(9):1075-1081.DOI:10.1111/dme.14050.
[21] Farina KA,Kane MP.Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus:a review of the literature[J].J Pharm Pract,2021,34(1):133-140.DOI:10.1177/0897190019850929.
[22] Chang LS,Barroso-Sousa R,Tolaney SM,et al.Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J].Endocr Rev,2019,40(1):17-65.DOI:10.1210/er.2018-00006.
[23] Arima H,Iwama S,Inaba H,et al.Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors:clinical guidelines of the Japan Endocrine Society [J].Endocr J,2019,66(7):581-586.DOI:10.1507/endocrj.EJ19-0163.
[24] Haanen JBAG,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up [J].Ann Oncol,2017,28(suppl_4):iv119-iv142.DOI:10.1093/annonc/mdx225.
[25] Aleksova J,Lau PK,Soldatos G,et al.Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma [J].BMJ Case Rep,2016,2016:bcr2016217454.DOI:10.1136/bcr-2016-217454.
[26] Noble JA,Valdes AM.Genetics of the HLA region in the prediction of type 1 diabetes [J].Curr Diab Rep, 2011,11(6):533-542.DOI:10.1007/s11892-011-0223-x.
[27] Tsutsumi C,Imagawa A,Ikegami H,et al.Class Ⅱ HLA genotype in fulminant type 1 diabetes:a nationwide survey with reference to glutamic acid decarboxylase antibodies [J].J Diabetes Investig,2012,3(1):62-69.DOI:10.1111/j.2040-1124.2011.00139.x.